ANI Pharmaceuticals ANIP Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Revenues by Business | ||||||
| Generics and Other | $405.61M+1.5% | $399.43M+5.2% | $379.63M+4.4% | $363.65M+4.4% | $348.26M+8.8% | |
| Rare Disease and Brands | $518.09M+7.1% | $483.93M+8.2% | $447.25M+16.5% | $383.75M+17.8% | $325.81M+10.7% | |
| Net Revenues by Product | ||||||
| Brands | $48.51M-20.9% | $61.31M-10.9% | $68.84M+2.2% | $67.36M+4.9% | $64.19M-0.9% | |
| Cortrophin Gel | $370.05M+6.4% | $347.78M+17.6% | $295.75M+20.0% | $246.45M+15.2% | $214M+8.0% | |
| Generic pharmaceutical products | $390.83M+1.8% | $384.11M+6.1% | $361.95M+4.7% | $345.8M+5.0% | $329.47M+9.5% | |
| ILUVIEN and YUTIQ | $78.01M+4.2% | $74.87M-9.4% | $82.67M+18.2% | $69.94M+46.9% | $47.62M+51.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ANI Pharmaceuticals break its business down?
- ANI Pharmaceuticals (ANIP) reports net revenues by business across 2 parts — Generics and Other and Rare Disease and Brands. Each is extracted from the segment footnotes and tracked over time.
- Where does ANI Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ANI Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
